Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer

Less than 50% of patients receiving salvage radiation therapy (SRT) to the pelvis as treatment for prostate cancer relapsing after surgery will achieve undetectable Prostate Specific Antigen (PSA) levels. Despite SRT, two-thirds of patients will again develop elevated PSA, 20% will have distant metastases, and 10% will die from prostate cancer within 10 years. The reason for this is probably preexisting distant metastasis and lymph node metastasises which need to better targeted directly. Additionally , there are well known permanent side effects to SRT. Standard imaging techniques have poor

Trial Details

NCT ID

NCT04794777

Phase

PHASE3

Sponsor

Stefan Carlsson

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Individualised therapy
Standard salvage therapy

Locations (sample)

Gothenburg, Göteborg, Sweden|57.70716,11.96679
Stockholm, Stockholm County, Sweden|59.32938,18.06871
Stockholm, Stockholm County, Sweden|59.32938,18.06871
Umeå, Sweden|63.82842,20.25972
Örebro, Örebro County, Sweden|59.27412,15.2066

Key Eligibility Criteria

Patients previously treated for prostate cancer with radical prostatectomy and now having a biochemical recurrence (BCR) defined as: PSA \>0.2 \<2.…
Multidisciplinary conference (MDK) decision to offer the patient SRT
Signed Informed Consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →